The diagnostic method of deciding the convalescence of the non small cell lung cancer

摘要

This invention the early non small cell lung cancer which possesses satisfactory convalescence concerning the recurrence of the lung cancer after the surgical excising (NSCLC) offers the method of identifying the patient. As for this invention, it is based on the knowledge that it can use the appraisal of chromosome copy several abnormalities in 2 kinds or more of chromosome 5p15, 7p12, 8q24 and 6th sentoromea for convalescence classification. This invention, desirably, the hybrid making the patient sample form, the number of chromosome of these heredity stromata copies you use fluorescent insaichiyuhaiburidaizeshiyon which uses the fluorescent sign nuclear acid probe in order to measure. Appraisal of copy several abnormal patterns which use the taxonomic index of 4 kinds concerning NSCLC brought significant convalescence classification statistically: 3 pattern of the range of the cell which at least shows the difference of the FISH probe signal of 3 where it pulled the FISH signal in the chromosome heredity stroma which possesses the smallest number of FISH signals from the FISH signal in the chromosome heredity stroma possessing the maximum amount of the (i) FISH signal in the cell base; The MYC/EGFR% loss pattern which appraises the percentage of the cell which shows the MYC FISH probe signal which is smaller than the (ii) EGFR FISH probe signal; Concerning 3 pattern, and CEP6 of the (iii) range combination of MYC/CEP6 ratio pattern of percentage of the cell which shows the relative loss of the MYC FISH probe signal for the FISH probe signal; Relative ratio with the (iv) MYC heredity stroma signal and the 5p15 heredity stroma signal relative ratio with the MYC/5p15 ratio pattern and the 5p15FISH probe signal and the CEP6FISH probe signal which =0.80 are shown combination of the 5p15/CEP6 ratio pattern which appraises the percentage of the cell which it possesses =1.1 and, 0.80 MYC/5p15 ratio or 5p15/CEP61.1; And combination with average range of the probe signal difference of (v) approximately 2.5 or more and 3 pattern of range of percentage of cell. Before the technique or after the technique can this invention, use in order early of these whose risk of the recurrence which it should remedy with adjuvant chemotherapy is higher to identify the NSCLC patient with neo adjuvant chemotherapy.